DMAC - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים DiaMedica Corp

This TTM year-over-year revenue chart illustrates the dynamics of DiaMedica Therapeutics (DMAC). Growth is driven by the final stages of DM199 trials for the therapy of strokes and renal pathologies. The lack of market alternatives and vascular restoration stimulate M&A potential. Raw material reserves in Europe and the US ensure stability. The value of 0.00 reflects the baseline level of the metric.
DiaMedica Corp (DMAC) - פילוחי מדדים ודוחות פיננסיים

This indicator captures the daily revenue dynamics over a rolling twelve-month period relative to the previous year, allowing for the identification of structural shifts in demand prior to the publication of quarterly reports. By analyzing this chart of the annual growth in sales volume for TTM, an investor can assess the effectiveness of the asset-light model of DiaMedica Therapeutics (DMAC), where the outsourcing of protein production is intended to ensure revenue scalability without capital expenditures.